Drug Profile


Alternative Names: 3,4-Dihydroxyphenylserine; 3,4-threo-DOPS; Dops; L-DOPS; L-threo-dihydroxyphenylserine; L-threodops; Northera; Threo-dopaserine; Threo-DOPS

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Chelsea Therapeutics; Lundbeck A/S; Sumitomo Dainippon Pharma
  • Class Amino acids; Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Orthostatic hypotension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Dizziness; Intradialytic hypotension; Orthostatic hypotension
  • Discontinued Attention-deficit hyperactivity disorder; Chronic fatigue syndrome; Fibromyalgia

Most Recent Events

  • 11 May 2015 No recent reports of development identified - Phase-II for Intradialytic hypotension in USA (PO)
  • 11 May 2015 No recent reports of development identified - Phase-III for Orthostatic hypotension in New Zealand, Australia, European Union and Canada (PO)
  • 01 Feb 2015 Chelsea Therapeutics completes a phase III trial in Orthostatic hypotension in USA (NCT01927055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top